Aidsmap·4 min read·hard
Alternative first-line HIV regimen limits excess weight gain
✦AI Summary
A South African study presented at the International AIDS Conference indicates that HIV treatment regimens containing doravirine and TDF result in less weight gain compared to those with dolutegravir and TAF. The findings highlight the challenge of managing side effects in long-term HIV care.
Starting treatment with a regimen containing doravirine and tenofovir disoproxil (TDF) resulted in less weight gain than starting treatment with a regimen containing dolutegravir and tenofovir alafenamide, a South African study reported yesterday week at the 26th International AIDS Conference in Rio de Janeiro, Brazil.
healthscience
✦
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in